Naoki Otani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Naoki Otani has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Atsuo Yoshino
Division of Neurosurgery, Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, JPN
7 shared publicationsKoichiro Sumi
Division of Neurosurgery, Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, JPN
3 shared publications- Atsuo Yoshino
Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan
2 shared publications Hideki Oshima
School of Medicine, Division of Neurosurgery, Department of Neurological Surgery, Nihon University, Tokyo, Japan
2 shared publications- Kentaro Mori
Department of Neurosurgery, Tokyo General Hospital, Tokyo, Japan
2 shared publications Ryuta Kajimoto
School of Medicine, Division of Neurosurgery, Department of Neurological Surgery, Nihon University, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 13 (4) , e81240040
Perampanel Effects on Sleep in Epilepsy Patients: A Pilot Case Series on Its Therapeutic Potential for Sleep Disorders
Background Sleep disorders are common among individuals with epilepsy, often leading to disturbances in sleep patterns and architecture. Certain anti-seizure medications adversely affect sleep independently of their anti-seizure effects. Objective This study aims to examine the impact of perampanel (PER) on sleep disorders in patients with epilepsy. Methods The effects of adjunctive PER therapy on circadian rhythm and daytime sleepiness were evaluated in epilepsy patients with comorbid sleep disorders. Twenty-one eligible patients were included, excluding those with liver failure or psychological disorders. This pilot case series assessed participants using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale. PER blood concentrations were measured. Patients were selected based on baseline PSQI scores ≥6 (mean 11.57 ± 2.77). Results After 3 months of PER administration, the mean global PSQI score significantly improved to 6.71 ± 5.00 (p<0.01). Improvements were observed in PSQI components: C1 (sleep quality), C2 (sleep latency), and C6 (frequency of sleep medication use). A strong positive correlation was found between changes in PSQI scores (delta-PSQI = post-PER − pre-PER score) and PER blood concentrations (r = 0.71, p<0.01). Conclusion Adjunctive PER therapy significantly improved subjective sleep quality in epilepsy patients with comorbid sleep disorders. The correlation between the magnitude of improvements and PER blood concentration suggests a dose–response relationship. These findings indicate that PER may be a beneficial therapeutic option for managing sleep disturbances in this population and support the need for further investigation in larger, controlled studies.
- 14 November 2025
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 13 (4) , e81240040
Open AccessPerampanel Effects on Sleep in Epilepsy Patients: A Pilot Case Series on Its Therapeutic Potential for Sleep Disorders
Background Sleep disorders are common among individuals with epilepsy, often leading to disturbances in sleep patterns and architecture. Certain anti-seizure medications adversely affect sleep independently of their anti-seizure effects. Objective This study aims to examine the impact of perampanel (PER) on sleep disorders in patients with epilepsy. Methods The effects of adjunctive PER therapy on circadian rhythm and daytime sleepiness were evaluated in epilepsy patients with comorbid sleep disorders. Twenty-one eligible patients were included, excluding those with liver failure or psychological disorders. This pilot case series assessed participants using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale. PER blood concentrations were measured. Patients were selected based on baseline PSQI scores ≥6 (mean 11.57 ± 2.77). Results After 3 months of PER administration, the mean global PSQI score significantly improved to 6.71 ± 5.00 (p<0.01). Improvements were observed in PSQI components: C1 (sleep quality), C2 (sleep latency), and C6 (frequency of sleep medication use). A strong positive correlation was found between changes in PSQI scores (delta-PSQI = post-PER − pre-PER score) and PER blood concentrations (r = 0.71, p<0.01). Conclusion Adjunctive PER therapy significantly improved subjective sleep quality in epilepsy patients with comorbid sleep disorders. The correlation between the magnitude of improvements and PER blood concentration suggests a dose–response relationship. These findings indicate that PER may be a beneficial therapeutic option for managing sleep disturbances in this population and support the need for further investigation in larger, controlled studies.
- Open Access
- 28 June 2025
- Published by Springer Nature in Cureus
- Vol. 17 (6) , e86940
The Surgical Management of Intractable Vertigo and Tinnitus Caused by Neurovascular Compression of the Auditory Vestibular Nerve: A Report of Two Cases and Review of the Literature
Neurovascular compression (NVC) of the auditory vestibular nerve (AVN) may be one of the causes of intractable dizziness and characteristic tinnitus, which are often described as typewriter-like tinnitus. While these symptoms can be alleviated by oral administration of carbamazepine (CBZ), no standard diagnostic and surgical indications and treatment methods have been established. Microvascular decompression (MVD) is effective for these disorders. We describe two cases where MVD resulted in favorable clinical outcomes, and we also review the relevant literature. Our experience suggests that MVD may be an effective treatment option for patients who exhibit a positive response to CBZ, show clear radiological evidence of NVC, and present with both tinnitus and vertigo.
- 28 June 2025
- Published by Springer Nature in Cureus
- Vol. 17 (6) , e86940
Open AccessThe Surgical Management of Intractable Vertigo and Tinnitus Caused by Neurovascular Compression of the Auditory Vestibular Nerve: A Report of Two Cases and Review of the Literature
Neurovascular compression (NVC) of the auditory vestibular nerve (AVN) may be one of the causes of intractable dizziness and characteristic tinnitus, which are often described as typewriter-like tinnitus. While these symptoms can be alleviated by oral administration of carbamazepine (CBZ), no standard diagnostic and surgical indications and treatment methods have been established. Microvascular decompression (MVD) is effective for these disorders. We describe two cases where MVD resulted in favorable clinical outcomes, and we also review the relevant literature. Our experience suggests that MVD may be an effective treatment option for patients who exhibit a positive response to CBZ, show clear radiological evidence of NVC, and present with both tinnitus and vertigo.
- 10 September 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 131, 110829
Modified colored three-dimensional posterior and temporal cranial fossa model with mobility of the joint between C1 and occipital condyle
- 10 September 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 131, 110829
Modified colored three-dimensional posterior and temporal cranial fossa model with mobility of the joint between C1 and occipital condyle
- Open Access
- 1 February 2024
- Published by The Nihon University Medical Association in Journal of Nihon University Medical Association
- Vol. 83 (1) , 33-36
Surgical Treatment For Intractable Vertigo And Tinnitus
- 1 February 2024
- Published by The Nihon University Medical Association in Journal of Nihon University Medical Association
- Vol. 83 (1) , 33-36
Open AccessSurgical Treatment For Intractable Vertigo And Tinnitus
- 1 July 2023
- Published by Edizioni Minerva Medica in Journal of Neurosurgical Sciences
- Vol. 67 (4) , 431-438
Glibenclamide reduces secondary brain injury in a SAH rat model by reducing brain swelling and modulating inflammatory response
Article: Effects of glibenclamide against early brain injury in rat after subarachnoid hemorrhage - Journal of Neurosurgical Sciences 2022 Apr 05 - Minerva Medica - Journals
- 1 July 2023
- Published by Edizioni Minerva Medica in Journal of Neurosurgical Sciences
- Vol. 67 (4) , 431-438
Glibenclamide reduces secondary brain injury in a SAH rat model by reducing brain swelling and modulating inflammatory response
Article: Effects of glibenclamide against early brain injury in rat after subarachnoid hemorrhage - Journal of Neurosurgical Sciences 2022 Apr 05 - Minerva Medica - Journals
- Open Access
- 16 January 2023
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Reports
- Vol. 84 (01) , e6-e10
Neurofibromatosis Type 1 with Giant Thrombotic Aneurysm of the Internal Carotid Artery Presenting with Rapid Progression of Visual Disturbance: A Case Report and Literature Review
Background Patients with neurofibromatosis type 1 (NF1) have various vascular diseases due to the vascular fragility, but no reports of case of giant thrombotic aneurysm was found. We treated a rare case of giant thrombotic aneurysm of the internal carotid artery (ICA) in a patient with NF1. Case Presentation A 60-year-old man had suffered deteriorating visual loss and homonymous hemianopia. Contrast-enhanced computed tomography showed a giant thrombosed aneurysm on the anterior wall of the ICA located in the optic chiasma. We planned and completed the external carotid artery-middle cerebral artery high-flow bypass using radial artery graft. The visual fields test was performed 14 days after surgery. Homonymous hemianopia persisted but no exacerbation of visual field impairment was observed. No complications were found at 14 days after surgery and the postoperative course was uneventful. Conclusion We consider that external carotid artery-middle cerebral artery bypass surgery using radial artery grafts is a safe and effective treatment method for giant thrombotic aneurysm associated with NF1.
- 16 January 2023
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Reports
- Vol. 84 (01) , e6-e10
Open AccessNeurofibromatosis Type 1 with Giant Thrombotic Aneurysm of the Internal Carotid Artery Presenting with Rapid Progression of Visual Disturbance: A Case Report and Literature Review
Background Patients with neurofibromatosis type 1 (NF1) have various vascular diseases due to the vascular fragility, but no reports of case of giant thrombotic aneurysm was found. We treated a rare case of giant thrombotic aneurysm of the internal carotid artery (ICA) in a patient with NF1. Case Presentation A 60-year-old man had suffered deteriorating visual loss and homonymous hemianopia. Contrast-enhanced computed tomography showed a giant thrombosed aneurysm on the anterior wall of the ICA located in the optic chiasma. We planned and completed the external carotid artery-middle cerebral artery high-flow bypass using radial artery graft. The visual fields test was performed 14 days after surgery. Homonymous hemianopia persisted but no exacerbation of visual field impairment was observed. No complications were found at 14 days after surgery and the postoperative course was uneventful. Conclusion We consider that external carotid artery-middle cerebral artery bypass surgery using radial artery grafts is a safe and effective treatment method for giant thrombotic aneurysm associated with NF1.
- 1 January 2022
- Published by Springer Nature
- Vol. 44, 79-96
Ischemic Stroke Revascularization
Extracranial-intracranial (EC-IC) bypass is one of the most fundamental techniques for ischemic cerebrovascular disease (CVD). We describe the standard surgical strategies, advanced techniques, and controversies concerning revascularization of ischemic stroke. The standard surgical strategies and techniques emphasize how to determine surgical indication, which should be decided for symptomatic internal carotid artery or middle cerebral artery (MCA) occlusive disease with misery perfusion detected by quantitative single photon emission computed tomography. Advanced techniques are available for complex situations such as posterior circulation revascularization, Bonnet bypass for common carotid artery obstruction, and various EC-IC bypasses for ischemia in the MCA and/or anterior cerebral artery territories using inter-grafts such as femoral veins and radial arteries, illustrated by our surgical results and experiences. Controversies include endovascular treatment complementary to EC-IC bypass. Finally, we advocate emergent EC-IC bypass for progressive ischemic CVD, particularly for contraindication or unsuccessful treatment after intravenous tissue plasminogen activator administration and/or endovascular thrombolysis. EC-IC bypass surgery can be reliable for ischemic CVD under strict optimal surgical indications using safe and reliable surgical techniques.
- 1 January 2022
- Published by Springer Nature
- Vol. 44, 79-96
Ischemic Stroke Revascularization
Extracranial-intracranial (EC-IC) bypass is one of the most fundamental techniques for ischemic cerebrovascular disease (CVD). We describe the standard surgical strategies, advanced techniques, and controversies concerning revascularization of ischemic stroke. The standard surgical strategies and techniques emphasize how to determine surgical indication, which should be decided for symptomatic internal carotid artery or middle cerebral artery (MCA) occlusive disease with misery perfusion detected by quantitative single photon emission computed tomography. Advanced techniques are available for complex situations such as posterior circulation revascularization, Bonnet bypass for common carotid artery obstruction, and various EC-IC bypasses for ischemia in the MCA and/or anterior cerebral artery territories using inter-grafts such as femoral veins and radial arteries, illustrated by our surgical results and experiences. Controversies include endovascular treatment complementary to EC-IC bypass. Finally, we advocate emergent EC-IC bypass for progressive ischemic CVD, particularly for contraindication or unsuccessful treatment after intravenous tissue plasminogen activator administration and/or endovascular thrombolysis. EC-IC bypass surgery can be reliable for ischemic CVD under strict optimal surgical indications using safe and reliable surgical techniques.
- Open Access
- 6 July 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 26, 101228
Emergency STA-MCA bypass surgery for symptomatic progressive ischemic stroke
- 6 July 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 26, 101228
Open AccessEmergency STA-MCA bypass surgery for symptomatic progressive ischemic stroke
- Open Access
- 17 March 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-6
Venous hypertension caused by a meningioma involving the sigmoid sinus: case report
Background: Intracranial venous hypertension has been associated with a few cases of meningioma secondary to compression of the venous sinus. This is the rare case of small meningioma involving the sigmoid sinus leading to intracranial venous hypertension mimicking venous thrombosis. Case presentation: A 39-year-old woman suffered visual dysfunction due to bilateral papilledema. Noncontrast head computed tomography (CT) showed no intracranial space-occupying lesions or hydrocephalus. Cerebrospinal fluid examination revealed high opening pressure. Various image inspections such as three-dimensional CT angiography, magnetic resonance imaging, and cerebral angiography demonstrated a small 2.5-cm lesion causing subtotal occlusion of the dominant right sigmoid sinus. No improvement of clinical manifestations was observed after medical treatment for 6 months, so right presigmoid craniectomy was performed. Operative findings revealed that the tumor was located predominantly involving the sigmoid sinus. The pathological diagnosis was fibrous meningioma. Postoperative fundoscopic examination showed improvement of bilateral papilledema. Conclusions: We treated a patient presenting with intracranial hypertension due to a small meningioma involving the sigmoid sinus. This unusual case suggests that early surgical strategies should be undertaken to relieve the sinus obstruction.
- 17 March 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-6
Open AccessVenous hypertension caused by a meningioma involving the sigmoid sinus: case report
Background: Intracranial venous hypertension has been associated with a few cases of meningioma secondary to compression of the venous sinus. This is the rare case of small meningioma involving the sigmoid sinus leading to intracranial venous hypertension mimicking venous thrombosis. Case presentation: A 39-year-old woman suffered visual dysfunction due to bilateral papilledema. Noncontrast head computed tomography (CT) showed no intracranial space-occupying lesions or hydrocephalus. Cerebrospinal fluid examination revealed high opening pressure. Various image inspections such as three-dimensional CT angiography, magnetic resonance imaging, and cerebral angiography demonstrated a small 2.5-cm lesion causing subtotal occlusion of the dominant right sigmoid sinus. No improvement of clinical manifestations was observed after medical treatment for 6 months, so right presigmoid craniectomy was performed. Operative findings revealed that the tumor was located predominantly involving the sigmoid sinus. The pathological diagnosis was fibrous meningioma. Postoperative fundoscopic examination showed improvement of bilateral papilledema. Conclusions: We treated a patient presenting with intracranial hypertension due to a small meningioma involving the sigmoid sinus. This unusual case suggests that early surgical strategies should be undertaken to relieve the sinus obstruction.
- Open Access
Enhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation
To manage refractory and invasive glioblastomas (GBM)s, photodynamic therapy (PDT) using talaporfin sodium (NPe6) (NPe6-PDT) was recently approved in clinical practice. However, the molecular machineries regulating resistance against NPe6-PDT in GBMs and mechanisms underlying the changes in GBM phenotypes following NPe6-PDT remain unknown. Herein, we established an in vitro NPe6-mediated PDT model using human GBM cell lines. NPe6-PDT induced GBM cell death in a NPe6 dose-dependent manner. However, this NPe6-PDT-induced GBM cell death was not completely blocked by the pan-caspase inhibitor, suggesting NPe6-PDT induces both caspase-dependent and -independent cell death. Moreover, treatment with poly (ADP-ribose) polymerase inhibitor blocked NPe6-PDT-triggered caspase-independent GBM cell death. Next, it was also revealed resistance to re-NPe6-PDT of GBM cells and GBM stem cells survived following NPe6-PDT (NPe6-PDT-R cells), as well as migration and invasion of NPe6-PDT-R cells were enhanced. Immunoblotting of NPe6-PDT-R cells to assess the behavior of the proteins that are known to be stress-induced revealed that only ERK1/2 activation exhibited the same trend as migration. Importantly, treatment with the MEK1/2 inhibitor trametinib reversed resistance against re-NPe6-PDT and suppressed the enhanced migration and invasion of NPe6-PDT-R cells. Overall, enhanced ERK1/2 activation is suggested as a key regulator of elevated malignant phenotypes of GBM cells surviving NPe6-PDT and is therefore considered as a potential therapeutic target against GBM.
Open AccessEnhanced Malignant Phenotypes of Glioblastoma Cells Surviving NPe6-Mediated Photodynamic Therapy are Regulated via ERK1/2 Activation
To manage refractory and invasive glioblastomas (GBM)s, photodynamic therapy (PDT) using talaporfin sodium (NPe6) (NPe6-PDT) was recently approved in clinical practice. However, the molecular machineries regulating resistance against NPe6-PDT in GBMs and mechanisms underlying the changes in GBM phenotypes following NPe6-PDT remain unknown. Herein, we established an in vitro NPe6-mediated PDT model using human GBM cell lines. NPe6-PDT induced GBM cell death in a NPe6 dose-dependent manner. However, this NPe6-PDT-induced GBM cell death was not completely blocked by the pan-caspase inhibitor, suggesting NPe6-PDT induces both caspase-dependent and -independent cell death. Moreover, treatment with poly (ADP-ribose) polymerase inhibitor blocked NPe6-PDT-triggered caspase-independent GBM cell death. Next, it was also revealed resistance to re-NPe6-PDT of GBM cells and GBM stem cells survived following NPe6-PDT (NPe6-PDT-R cells), as well as migration and invasion of NPe6-PDT-R cells were enhanced. Immunoblotting of NPe6-PDT-R cells to assess the behavior of the proteins that are known to be stress-induced revealed that only ERK1/2 activation exhibited the same trend as migration. Importantly, treatment with the MEK1/2 inhibitor trametinib reversed resistance against re-NPe6-PDT and suppressed the enhanced migration and invasion of NPe6-PDT-R cells. Overall, enhanced ERK1/2 activation is suggested as a key regulator of elevated malignant phenotypes of GBM cells surviving NPe6-PDT and is therefore considered as a potential therapeutic target against GBM.